HERPESVIRUS VACCINES
1. Immunization with Epstein–Barr virus core fusion machinery envelope proteins elicit high titers of neutralizing activities and protect humanized mice from lethal dose EBV challenge, Cui, X, Snapper, C.M. Vaccines, 2021, 9. 285.
2. Immunization with human cytomegalovirus core fusion machinery and accessory envelope proteins elicit strong synergistic neutralizing activities. Cui, X, Snapper, CM. Vaccines, 2020; 8(2): E179.
3. Development of novel vaccines against human cytomegalovirus. Cui X, Snapper CM. Hum Vaccin Immunother. 2019; 15(11): 2673-83
4. Novel trimeric human cytomegalovirus glycoprotein B elicits a high-titer neutralizing antibody response. Cui X, Snapper CM. Vaccine. 2018; 36(37): 5580-90.
5. Immunization of rabbits with recombinant human cytomegalovirus trimeric versus monomeric gH/gL protein elicits markedly higher titers of antibody and neutralization activity. Cui X, Snapper CM. Int J Mol Sci. 2019, 20 (13): 3158.
6. Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350. Cui X, Snapper CM. Vaccine. 2016; 34(34): 4050-55.
7. A novel tetrameric gp350 (1-470) as a potential Epstein-Barr virus vaccine. Cui X, Snapper CM. Vaccine. 2013; 31(30): 3039-45.
1. Immunization with Epstein–Barr virus core fusion machinery envelope proteins elicit high titers of neutralizing activities and protect humanized mice from lethal dose EBV challenge, Cui, X, Snapper, C.M. Vaccines, 2021, 9. 285.
2. Immunization with human cytomegalovirus core fusion machinery and accessory envelope proteins elicit strong synergistic neutralizing activities. Cui, X, Snapper, CM. Vaccines, 2020; 8(2): E179.
3. Development of novel vaccines against human cytomegalovirus. Cui X, Snapper CM. Hum Vaccin Immunother. 2019; 15(11): 2673-83
4. Novel trimeric human cytomegalovirus glycoprotein B elicits a high-titer neutralizing antibody response. Cui X, Snapper CM. Vaccine. 2018; 36(37): 5580-90.
5. Immunization of rabbits with recombinant human cytomegalovirus trimeric versus monomeric gH/gL protein elicits markedly higher titers of antibody and neutralization activity. Cui X, Snapper CM. Int J Mol Sci. 2019, 20 (13): 3158.
6. Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350. Cui X, Snapper CM. Vaccine. 2016; 34(34): 4050-55.
7. A novel tetrameric gp350 (1-470) as a potential Epstein-Barr virus vaccine. Cui X, Snapper CM. Vaccine. 2013; 31(30): 3039-45.
VACCINE DEVELOPMENT: FROM CONCEPT TO CLINIC
Editor: A, Krishna Prasad
Publisher: Royal Society of Chemistry (2022)
https://pubs.rsc.org/en/content/ebook/978-1-78801-877-7
Editor: A, Krishna Prasad
Publisher: Royal Society of Chemistry (2022)
https://pubs.rsc.org/en/content/ebook/978-1-78801-877-7
CONJUGATE VACCINES
1. Glycoconjugates: What it takes to master these well-known yet little understood immunogens for vaccine development. F. Avci, F. Berti, P. Dull, J. Hennessey, V. Pavliak, A. Krishna Prasad, W. Vann, M. Wacker, O. Marcq. mSphere, 2019, Sep 25; 4(5):e00520-19.
2. CARBOHYDRATE-BASED VACCINES: FROM CONCEPT TO CLINIC. Editor: A. Krishna Prasad, Oxford University Press, 2019.
1. Glycoconjugates: What it takes to master these well-known yet little understood immunogens for vaccine development. F. Avci, F. Berti, P. Dull, J. Hennessey, V. Pavliak, A. Krishna Prasad, W. Vann, M. Wacker, O. Marcq. mSphere, 2019, Sep 25; 4(5):e00520-19.
2. CARBOHYDRATE-BASED VACCINES: FROM CONCEPT TO CLINIC. Editor: A. Krishna Prasad, Oxford University Press, 2019.
CARBOHYDRATE-BASED VACCINES: FROM CONCEPT TO CLINIC (BOOK).
Editor: A. Krishna Prasad tinyurl.com/cbvdigital |